A Novel Drug Delivery System of Oral Curcumin Markedly Improves Efficacy of Treatment for Heart Failure after Myocardial Infarction in Rats

Curcumin is an inhibitor of p300 histone acetyltransferase activity, which is associated with the deterioration of heart failure. We reported that native curcumin, at a dosage of 50mg/kg, prevented deterioration of the systolic function in rat models of heart failure. To achieve more efficient oral...

Full description

Saved in:
Bibliographic Details
Published inBiological and Pharmaceutical Bulletin Vol. 35; no. 2; pp. 139 - 144
Main Authors Yoichi Sunagawaa, b, c, Hiromichi Wadab, Hidetoshi Suzukic, Hiroki Sasakid, Atsushi Imaizumid, Hiroyuki Fukudad, Tadashi Hashimotod, Yasufumi Katanasakac, Akira Shimatsue, Takeshi Kimuraf, Hideaki Kakeyag, Masatoshi Fujitaa, Koji Hasegawab, Tatsuya Morimotoc
Format Journal Article
LanguageJapanese
Published Pharmaceutical Society of Japan 2012
Online AccessGet full text

Cover

More Information
Summary:Curcumin is an inhibitor of p300 histone acetyltransferase activity, which is associated with the deterioration of heart failure. We reported that native curcumin, at a dosage of 50mg/kg, prevented deterioration of the systolic function in rat models of heart failure. To achieve more efficient oral pharmacological therapy against heart failure by curcumin, we have developed a novel drug delivery system (DDS) which markedly increases plasma curcumin levels. At the dosage of 0.5mg/kg, DDS curcumin but not native curcumin restored left ventricular fractional shortening in post-myocardial infarction rats. Thus, our DDS strategy will be applicable to the clinical setting in humans.
ISSN:0918-6158
1347-5215